Sudarshan Pharma Industries Ltd · BSE:SUDARSHAN
Sudarshan Pharma Industries — Investor Presentation (May 2025)
42 slides from Sudarshan Pharma Industries's investor presentation, May 2025
Slide 1: Sudarshan Pharma Industries Limited Investor Presentation
Sudarshan Pharma Industries Limited Investor Presentation
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sudarshan Pharma Industries Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or s
Slide 3: H2 & FY25 Financial & Operational Performance
H2 & FY25 Financial & Operational Performance
Slide 4: H2 & FY25 Financial Metrics: Focus on Margin Optimization and Profit Growth
H2 & FY25 Financial Metrics: Focus on Margin Optimization and Profit Growth Revenue from Operations Operating EBITDA & EBITDA Margin (%) PAT & PAT Margin (%) INR in Crs 7.3% 6.2% 8.4% 4.9% 7.9% 2.6% 2.8% 3.2% 2.5% 3.6% +9.0% +75.0% +39.3% 505.0 463.5 39.9 16.0 +51.9% +19.6% +62.0% 11.5 23.4 10.0 277
Slide 5: H2 & FY25 Consolidated Profit & Loss Statement
H2 & FY25 Consolidated Profit & Loss Statement Particulars (Rs.Crs) H2FY25 H2FY24 Y‐o‐Y H1FY25 H‐o‐H FY25 FY24 Y‐o‐Y Revenue from Operations 277.3 231.7 19.6% 227.8 21.7% 505.0 463.5 9.0% Cost of Material Consumed/Other Direct Costs 5.3 3.2 3.7 8.9 6.3 Purchases of Stock-in trade 273.2 209.8 211.9 4
Slide 6: Consolidated Balance Sheet
Consolidated Balance Sheet EQUITY & LIABILITIES (INR. Crs) Mar-25 Mar-24 ASSETS (Rs. Crs) Mar-25 Mar-24 Equity Share Capital 24.1 24.1 Property, Plant and Equipment 20.0 20.5 Reserves & Surplus 103.6 87.6 Capital work-in-progress 6.0 1.9 Money Received Towards Warrant 3.8 0.0 Intangible assets 0.3 0
Slide 7: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (INR in Cr) Mar-25 Mar-24 Profit before Tax 21.6 15.2 Adjustment for Non-Operating Items 20.0 9.4 Operating Profit before Working Capital Changes 41.6 24.6 Changes in Working Capital -3.5 -16.5 Cash Generated from Operations 38.2 8.2 Less: Direct Taxes pa
Slide 8: Working Capital Break-up
Working Capital Break‐up Working Capital Management (in Days) Net Working Capital (in Days) 28 63 64 54 116 101 96 75 75 73 68 66 64 59 48 45 Mar-22 Mar-23 Mar-24 Mar‐25 Inventory Debtors Creditors Sudarshan Pharma Industries Limited | Investor Presentation 8
Slide 9: Industry Overview
Industry Overview
Slide 10: Industry Overview
Industry Overview Indian Pharmaceutical Market (US$ billion) • US$ 50 bn India's pharmaceutical market in 2024 from US$ 42 bn in 2021. It is likely to reach ~US$ 66 bn by 2025 and further expand to reach ~US$ 120-130 bn by 2030. 450 • 40% of generic demand in the US, and 25% of all medicine in the U
Slide 11: Pharma Industry: Key Catalysts for Growth
Pharma Industry : Key Catalysts for Growth Recognizing the potential for growth, the Government of India took up the initiative of developing the Indian Pharmaceuticals sector by creating a separate Department in July 2008. The Department is entrusted with the responsibility of policy, pIanning, dev
Slide 12: India - A Strong Exporter Of Pharma & Specialty Chemicals Globally
INDIA‐ A Strong Exporter Of Pharma & Specialty Chemicals Globally A significant and rising player in the Global Pharmaceutical industry India’s drugs and pharmaceutical exports FDI inflows in the Indian drugs and Pharma sector stood at US$ 26.5 billion in FY24 reached US$236 Mn. between April 2023-J
Slide 13: Key Problem Area
Key Problem Area Dependence on China for Import of key APIs Categories Imports from China (%) Antibiotics 75-80 Hormones, Prostaglandins, Thromboxane & Leukotrienes 50-55 Pro-Vitamins & Vitamins 55-60 Other heterocyclic compounds 80-85 Other organic compounds 70-75 India imports ~70% of Intermediate
Slide 14: Addressing the Problem
Addressing the Problem The central government has earmarked ~Rs { @ 100 billion for the bulk drug industry, including Rs 30 billion for the promotion of bulk drug 3 parks (for the next five years) and Rs 69.4 billion for a production-linked incentive scheme for the promotion of domestic manufacturin
Slide 15: Company Overview
Company Overview
Slide 16: A Specialty Chemicals & Pharmaceutical Manufacturing Company
A Specialty Chemicals & Pharmaceutical Manufacturing Company 17 Years Founded in 2008, Sudarshan Pharma Industries Limited (SPIL) is engaged in manufacturing and sourcing of Chemicals and Pharmaceutical products Diversified Products The Company specializes in host of products from rock chemicals int
Slide 17: Milestones
Milestones 2011- 2013- 2015- 2017- 2019- 2021- 2023- 2012 2014 2016 2018 2020 2022 2024 • Generic formulations • Established our • Over 5,000 medical • Manufacturing of • Launch Hart Kit • IVD-Section Got 50Cr. • Developing new for institution supply, footprints in Gujarat, practitioners Nutraceutic
Slide 18: Organizational Chart: Companies and Subsidiaries
Organizational Chart: Companies and Subsidiaries SUDARSHAN PHARMA INDUSTRIES LTD. Ratna Lifescience Pvt. Ltd., a 100% subsidiary of Life Science Chemical Pvt Ltd. is in the business Ishwari Healthcare Pvt. Ltd, The company Sudarshan Pharma Industries Ltd, focuses on to carry on business as manufactu
Slide 19: Ratna Lifescience: Turnaround story
Ratna Lifescience : Turnaround story Revenue from Operations (Rs Mn) Profit After Tax (Rs Mn) 92.2 Over the past three years, the company was 7.1 operating at a loss. Since the takeover by Sudarshan Pharma Industries Ltd., we have 21.5 successfully turned it around into a profitable 5.0 0.2 -2.4 org
Slide 20: New Acquisitions & Partnerships
New Acquisitions & Partnerships Ardes Laboratories Pvt Ltd Daundi Biological Pvt Ltd • In November 2024, Sudarshan Pharma Industries Ltd. and • The Company has formalized a Rent Agreement with M/s. Ardes Laboratories Pvt. Ltd., Hyderabad, Telangana, entered Daundi Biological Private Limited for the
Slide 21: Business Verticals
Business Verticals Business Model The company is focusing on increasing manufacturing capabilities and has started Vertical Integration for expansion in the following segments: Branded Generics Finished Formulation and F&O Research & Development API Manufacturing and Import Intermediates for API Che
Slide 22: Key Products
Key Products SPECIALITY GREEN CHEMICALS Acetonitrile Tetrahydrofuran (THF) 1,4-Dioxane DMF/DMSO Meta xylene N-Heptane Diethanolamine NMP (N-Methyl-2-pyrrolidone) PHARMA DIVISION Out of 96 products, 56 are registered under the “R” Trade Mark. • SPIL has introduced a novel drug delivery system under t
Slide 23: Our Esteemed Clientele
Our Esteemed Clientele Sudarshan Pharma Industries Limited | Investor Presentation 23
Slide 24: Operating in over 10 countries globally
Operating in over 10 countries globally Exporting Countries Jordan Lebanon Nepal Qatar Saudia UAE Arabia Mali Bangladesh Oman Nigeria Sri Lanka Uganda Ghana Somalia Congo Kenya South Africa PAN India presence Sudarshan Pharma Industries Limited | Investor Presentation 24
Slide 25: Lead Management
Lead Management Mr. Hemal V. Mehta |Chairman & Management Director Hemal Mehta, the Founder and Chairman of Sudarshan Pharma Industries Ltd., brings 26 years of extensive experience in the pharmaceutical and chemical manufacturing industry. He is recognized for his expertise in innovation and techno
Slide 26: Strengthening Senior Management
Strengthening Senior Management Mr. Manoj Lodha |CFO Mr. Manoj Lodha is a Commerce graduate with professional qualifications as a Chartered Accountant, Cost Accountant, and a Law graduate from Mumbai. He joined the company in 1995, initially overseeing lender coordination, fundraising initiatives, a
Slide 27: Board of Directors
Board of Directors Umesh Luthra| Independent Director Jaya Sharma | Independent Director Registered as an Independent Director with the Result oriented Biotech Professional with General databank of IICA. She has authored ~ numerous write- Management knowledge having about 29+ years of ups on corpora
Slide 28: Key Personnel
Key Personnel Senior Key Personnel Existing Key Personnel Dr. Vishwas Joshi Mr. Nirav Shah Mr. Amit Mehta Mrs. Namrata Mehta Company Secretary Purchase Manager Vice president Sales Mr. Shailesh Bathiya Mr. Shrinivas Patil Mr. Milan shah Mrs. Shrishti Mayekar Export Head Purchase Manager Sales Head D
Slide 29: Recent Developments & Way Forward
Recent Developments & Way Forward
Slide 30: R&D for New Molecules & New Technology in association with Amity University
R&D for New Molecules & New Technology in association with Amity University SPIL has entered into a strategic partnership with Dr. William Selvamurthy at Amity University, a distinguished leader in global education who has established a benchmark for excellence by aligning educational practices, the
Slide 31: Investments under the Government PLI Programme
Investments under the Government PLI Programme The company has received approval under the Production Linked Incentive (PLI) scheme to promote the domestic manufacturing of critical Key Starting Materials (KSM), Drug Intermediates (DIs), and Active Pharmaceutical Ingredients (APIs) in India. Unit 1:
Slide 32: Sudarshan Group's Pharma Project Gains 40% PSI-2019 Subsidy
Sudarshan Group's Pharma Project Gains 40% PSI‐2019 Subsidy Maharashtra Govt. Subsidies for new project • Pharma Items Manufacturing Project by Sudarshan Group at Mahad MIDC (C Zone) has following subsidy benefits from State Government of Maharashtra, Industries Department , Under PSI-2019 scheme. •
Slide 33: New Manufacturing Facility
New Manufacturing Facility • The company has established Unit 2 in Palghar, Maharashtra • The facility's core operations cover a broad spectrum of activities, including raw material testing, formulation dispensing, batch manufacturing in line with approved standards, as well as packaging, storage, a
Slide 34: New Products & Markets
New Products & Markets Some of Our New Products : New Clientele: Chemical Sector: Pharma Sector: Oncology API’s: • 1, 4-Dioxane • Fluconazole, • Gemcitabine • 2 Methyl THF • Levocetrizine Dihydrochloride, • T9 • Acetonitrile • Chlorozoxazone, • Apalutamide • IODINE • Pregabalin, • Olaparib • Pyridin
Slide 35: Future Outlook
Future Outlook Strategic Expansion into New Products & Markets Establishing a State-of-the-Art Launching of Advanced Focusing on Product Innovation Expanding Pharma Sales Manufacturing Facility Healthcare Solutions and Market Penetration Domestically and Globally The company is focusing on increasin
Slide 36: Annexure
Annexure
Slide 37: Performance in Charts
Performance in Charts Revenue from Operations (Rs Cr) EBITDA (Rs Cr) PAT (Rs Cr) 3.1% 3.2% 4.9% 7.9% 1.5% 1.5% 2.5% 3.2% +12% 463.5 505.0 39.9 +45% 16.0 461.3 +54% 357.1 11.5 22.8 14.7 7.0 10.9 5.2 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 R0CE (%) ROE (%) Debt to Equity (x) 39.9 2
Slide 38: Historical Consolidated Profit & Loss Statement
Historical Consolidated Profit & Loss Statement Particulars (Rs.Crs) FY24 FY23 FY22 FY21 Revenue from Operations 463.5 461.3 357.1 193.4 Cost of Material Consumed/Other Direct Costs 6.3 0.3 0.0 1.7 Purchases of Stock-in trade 424.0 457.2 358.0 184.2 Change in Inventories of Finished goods & Work in
Slide 39: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (INR in Cr) Mar-24 Mar-23 Mar-22 Mar-21 Profit before Tax 15.2 9.5 7.1 3.6 Adjustment for Non-Operating Items 9.4 5.8 4.0 3.9 Operating Profit before Working Capital Changes 24.6 15.3 11.2 7.4 Changes in Working Capital -16.5 -42.0 -13.2 -3.7 Cash Generat
Slide 40: Consolidated Balance Sheet
Consolidated Balance Sheet EQUITY & LIABILITIES (INR. Crs) Mar-24 Mar-23 Mar-22 Mar-21 ASSETS (Rs. Crs) Mar-24 Mar-23 Mar-22 Mar-21 Equity Share Capital 24.1 24.1 9.7 9.5 Property, Plant and Equipment 20.5 19.0 6.3 6.0 Reserves & Surplus 87.6 76.9 20.0 13.0 Non-Controlling Interest 0.0 0.0 0.0 0.0 C
Slide 41: Participated in the GlobeChemShow - International Exhibition 2024
Participated in the GlobeChemShow – International Exhibition 2024 In 2025, the chemical and pharmaceutical industries are projected to prioritize innovation, sustainability, and resilience as key drivers of efficiency and growth Sudarshan Pharma Industries Limited | Investor Presentation 41
Slide 42: Thank You
For further information, please contact: Company : Sudarshan Pharma Industries Limited CIN: L51496MH2008PLC184997 Name - Mr. Nirav Shah Title - Company Secretary Email - compliance@sudarshanpharma.com Investor Relations Advisors : Mr. Nikunj Jain | Mr. Aiman Khan +91 97690 60608 | +91 90824 10984 ni
Sudarshan Pharma Industries — Investor Presentation (May 2025) on 6ix